Quectel Unveils Next Generation SG885G-WF Android Smart Module Ideal for High-Performance Industrial and Consumer IoT Applications
24.7.2023 12:00:00 EEST | Business Wire | Press release
Quectel Wireless Solutions, a global IoT solutions provider, today launches its new generation flagship Android smart module, the SG885G-WF. With high performance and rich media functions, the smart module is ideal for industrial and consumer applications that require high processing power and multimedia functions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230724716405/en/
Quectel unveils next generation SG885G-WF Android smart module ideal for high-performance industrial and consumer IoT applications. (Photo: Business Wire)
The module is powered by the Qualcomm® QCS8550 System-on-Chip (SoC) for IoT from Qualcomm Technologies, Inc., delivering an impressive combination of flexibility and performance. It supports Wi-Fi 7, Bluetooth 5.3, and incorporates 2x2 Wi-Fi MIMO technology, providing users with enhanced connectivity options.
“Qualcomm Technologies is proud to collaborate with Quectel on their SG885G-WF to bring high performance connectivity solutions to consumers,” stated Dev Singh, Vice President, Business Development, Qualcomm Technologies, Inc. “Utilizing Quectel’s extensive infrastructure of cellular modules, the SG855G-WF exemplifies the necessary capabilities needed to adapt to tomorrow’s technology in IoT and beyond.”
With computing power of up to 48 TOPS, the module offers robust video capabilities, including video encoding at 4K at 120 fps or 8K at 30 fps, as well as video decoding at 4K at 240 fps or 8K at 60 fps. This ensures smooth and high-quality video processing for various applications.
Measuring 49.0mm x 51.0mm x 4.25mm, the SG885G-WF is suitable for global deployments and offers 12 GB LPDDR5X plus 256GB UFS memory. In addition, the module offers a rich set of interfaces that include LCM, camera, I2S, PCIe, UART, USB, I2C and SPI. These, in addition to adoption of the Android operating system, extend the module’s applicability to wide range of IoT and M2M applications including videoconferencing systems, live streaming devices, gaming, computing, robots, drones, AR/VR, intelligent retail and safety.
Quectel provides a range of high-performance antennas that greatly enhance wireless connectivity, aiming to assist customers in streamlining their design processes. By combining Quectel's antennas with the SG885G-WF Android Smart module, IoT developers can effectively reduce both time-to-market and costs associated with their IoT devices.
Moreover, the module offers the advantage of seamless integration with Quectel's range of cellular modules, enhancing connectivity, flexibility, and integration possibilities even further.
“We’re proud to launch our new flagship Android smart module with the new generation Quectel SG885G-WF,” said Norbert Muhrer, President and CSO, Quectel Wireless Solutions. “The powerful Qualcomm chipset along with support for Wi-Fi 7, Bluetooth 5.3 and 2x2 MIMO technology provides customers with a powerful module that offers connectivity choice and a wide variety of interfaces. As IoT matures, the ability to enable applications that need high processing power for AI and multimedia functions has become essential and the SG885G-WF has been designed to meet these needs.”
The Quectel SG885G-WF also offers three high-current flash LED drivers which support both flash and torch modes in addition to charging management capability which supports battery voltage detection, fuel gauge and battery temperature detection. Audio interfaces include SWR, digital microphone, MI2S and HIFI I2S.
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of 5,900 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules, antennas, services and IoT connectivity.
With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.
For more information: www.quectel.com, LinkedIn, Facebook, and Twitter.
Qualcomm is a trademark or registered trademark of Qualcomm Incorporated.
Qualcomm branded products are products of Qualcomm Technologies, Inc. and/or its subsidiaries. Qualcomm patented technologies are licensed by Qualcomm Incorporated.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230724716405/en/
Contact information
Media: media@quectel.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom